Jonathan Cross, MD
Neurology · Aventura, FLNPI 1336146927
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 22.4%. 2025 is the largest year on record at $29,460, more than ten times the $315 reported in 2019. Among neurology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 743 payments — averaging $62.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$10K
- Eisai Inc.$9K
- Argenx US, Inc.$6K
- Biogen$3K
- Pfizer$2K
- Abbott$2K
- plus $14K from 54 others
Across 154 payments — averaging $6252.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$554K
- Vertex$278K
- Ipsen Innovation$130K
- Novartis$329
What the payments were for
- Consulting fees$18,34840%
- Speaking & faculty fees$2,2505%
- Travel & lodging$6,95215%
- Food & beverage$18,37040%
- Education$2060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,125 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 64 | $407,023 |
| NuplazidPimavanserin Tartrate | 54 | $344,654 |
| IngrezzaValbenazine Tosylate | 26 | $213,431 |
| Radicava OrsEdaravone | 13 | $180,232 |
| AustedoDeutetrabenazine | 13 | $164,722 |
| Austedo XrDeutetrabenazine | 12 | $157,474 |
| RytaryCarbidopa/Levodopa | 133 | $139,558 |
| GocovriAmantadine Hcl | 21 | $74,657 |
| Emgality PenGalcanezumab-Gnlm | 44 | $46,585 |
| Aimovig AutoinjectorErenumab-Aooe | 27 | $36,965 |
| UbrelvyUbrogepant | 25 | $30,893 |
| NeuproRotigotine | 21 | $29,990 |
| Emgality SyringeGalcanezumab-Gnlm | 17 | $26,219 |
| RexultiBrexpiprazole | 13 | $20,797 |
| BriviactBrivaracetam | 11 | $15,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $62 | $407,02364 claims |
| Acadia Pharmaceuticals IncNuplazid | $271 | $344,65454 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,221 | $322,19625 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $665 | $213,43126 claims |
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $173 | $140,452146 claims |
| MDD US Operations, LLCGocovri | $786 | $74,65721 claims |
| UCB, Inc.Neupro, Briviact | $2,019 | $45,09732 claims |
| AbbVieUbrelvy | $10,328 | $30,89325 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $397 | $20,79713 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $139 | $8,92018 claims |
| Almatica Pharma LLCSertraline Hcl | $16 | $62555 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.
Other neurology in Aventura
- Julie SchwartzbardAventura$444K
- Jeffrey GelblumAventura$324K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.